Piramal Pharma Limited
Piramal Pharma Limited, a prominent player in the global pharmaceutical industry, is headquartered in India and operates extensively across key regions, including North America, Europe, and Asia. Founded in 1988, the company has achieved significant milestones, establishing itself as a leader in both contract development and manufacturing, as well as in the formulation of complex generics. Piramal Pharma's core offerings include a diverse range of pharmaceutical products and services, with a strong emphasis on innovative drug delivery systems and advanced therapies. Their commitment to quality and sustainability sets them apart in a competitive market. With a robust portfolio and a focus on research and development, Piramal Pharma Limited continues to enhance its market position, contributing to healthcare solutions worldwide.
DitchCarbon Score
How does Piramal Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Piramal Pharma Limited's score of 31 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Piramal Pharma Limited's reported carbon emissions
In 2023, Piramal Pharma Limited reported total greenhouse gas emissions of approximately 55229000 kg CO2e for Scope 1, 75494000 kg CO2e for Scope 2, and 450639000 kg CO2e for Scope 3 emissions. This reflects a commitment to transparency in their carbon footprint across all scopes of emissions. Piramal Pharma has set ambitious climate targets, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline year. Additionally, the company is committed to a 25% reduction in absolute Scope 3 emissions, which encompass emissions from purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, and the use of sold products, also by FY2030. These targets align with industry standards and are classified under the Science Based Targets initiative (SBTi), ensuring that their reduction goals are consistent with the global aim to limit warming to 1.5°C. The commitment includes considerations for land-related emissions and removals from bioenergy feedstocks, highlighting a comprehensive approach to sustainability. Piramal Pharma's ongoing efforts reflect a proactive stance in addressing climate change and reducing their environmental impact within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 41,396,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,243,220 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 477,407,000 | - | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Piramal Pharma Limited is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
